In the I-SPY clinical trial (NCT01042379), SYD985 is being tested in combination with several drugs plus chemotherapy in the neoadjuvant setting, with paclitaxel (NCT04602117) or with PARP inhibitors (NCT04235101) in HER2+ or HER2-low breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.